市传内地医保谈判成功品种药物降价幅度不逾50%
据《央视新闻》报道,今年国家医保药品目录准入谈判今日在北京启动,此次谈判为期三天,涉及到癌症、精神疾病、眼病、儿科等药品品种。昨日上午参与谈判的约10家企业中,至少有两个为中成药独家品种,至少一款为糖尿病药物,至少有3家跨国药企参与,包括礼来和诺华。
据上午现场消息汇总来看,谈判成功的品种下降幅度均未超过50%,去年平均降幅为60.7%。上午基本上是独家品种,与条件5产品契合度较高。其中,至少有两个为中成药独家品种,至少一款为糖尿病药物,至少有3家跨国药企参与,包括礼来和诺华。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.